DNOW Reports First Quarter 2025 Results
Earnings Conference Call
8:00 a.m. CT
1 (888) 660-6431 (within North America)
1 (929) 203-2118 (outside North America)
Access Code: 7372055
Webcast: ir.dnow.com
HOUSTON--(BUSINESS WIRE)--DNOW Inc. (NYSE: DNOW) announced results for the first quarter ended March 31, 2025.
Recent Capital Allocation Actions
Repurchased $8 million of common stock in the first quarter of 2025, and $16 million year-to-date, under the $160 million share repurchase program authorized this year
Completed acquisition of Natron International Pte. Ltd in April, headquartered in Singapore, which expands our electrical supply capabilities under the MacLean International brand in the Asia Pacific region, serving traditional and renewable energy, infrastructure and other commercial and industrial end-markets
Financial Highlights
Revenue was $599 million for the first quarter of 2025
Net income attributable to DNOW Inc. was $22 million, or $0.20 per diluted share, for the first quarter of 2025
Non-GAAP net income attributable to DNOW Inc. excluding other costs was $24 million, or $0.22 per diluted share, for the first quarter of 2025
EBITDA excluding other costs was $46 million or 7.7% of revenue for the first quarter of 2025
Invested $33 million in additional inventory, with cash used in operating activities of $16 million for the first quarter of 2025
Cash and cash equivalents was $219 million and long-term debt was zero at March 31, 2025, with total liquidity of approximately $567 million
David Cherechinsky, President and CEO of DNOW, added, 'Following our second-best fourth quarter in history, we beat first-quarter expectations with revenue growth of 5% sequentially to $599 million, and delivered our second-best first-quarter EBITDA of $46 million, in a market with fewer operating rigs and completions.
We executed adroitly on our capital allocation initiatives, closing on a small important acquisition in Singapore to expand our MacLean International offering. We repurchased $16 million of common stock on a year-to-date basis, under our new $160 million share repurchase program, while strategically adding $33 million in inventory for organic growth, which should set us up favorably in this environment.
We are uniquely well-capitalized, with a significant cash balance and no debt or interest payments and can be selective and patient at the acquisition bargaining table while benefiting from our fortuitous inventory planning.
While future market conditions are difficult to predict, given uncertainties stemming from the decline in oil prices and tariff-induced trade disruptions, we believe we are well positioned to seize organic, adjacent and inorganic growth opportunities, pursuing more efficient and cost-effective ways to execute operationally.
I want to extend my sincerest gratitude to the women and men of DNOW who distinguish us in the market with how we promote our key manufacturers and work tirelessly to delight our customers, as we build upon a great start to the year.'
Prior to the earnings conference call a presentation titled 'DNOW First Quarter 2025 Key Takeaways' will be available on the Company's Investor Relations website.
About DNOW
DNOW is a supplier of energy and industrial products and packaged, engineered process and production equipment with a legacy of over 160 years. Headquartered in Houston, Texas, with approximately 2,600 employees and a network of locations, we offer a broad set of supply chain solutions combined with a suite of digital offerings branded as DigitalNOW® that provide customers access to highly complementary digital commerce, data and information management channels. Our locations provide products and solutions to exploration and production, midstream transmission and storage companies, refineries, chemical companies, utilities, mining, municipal water, manufacturers, engineering and construction as well as companies operating in the decarbonization, energy evolution and renewables end markets.
Statements made in this press release that are forward-looking in nature are intended to be "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934 and may involve risks and uncertainties. These statements may differ materially from actual future events or results. Readers are referred to documents filed by DNOW Inc. with the U.S. Securities and Exchange Commission, which identify significant risk factors which could cause actual results to differ from those contained in the forward-looking statements.
DNOW INC.
(In millions, except per share data)
Three Months Ended
March 31, December 31,
2025
2024
2024
Revenue
$
599
$
563
$
571
Operating expenses:
Cost of products
460
434
438
Warehousing, selling and administrative
109
101
103
Impairment and other charges
−
−
1
Operating profit
30
28
29
Other income (expense)
−
1
1
Income before income taxes
30
29
30
Income tax provision
7
8
7
Net income
23
21
23
Net income attributable to noncontrolling interest
1
−
−
Net income attributable to DNOW Inc.
$
22
$
21
$
23
Earnings per share attributable to DNOW Inc. stockholders:
Basic
$
0.20
$
0.20
$
0.22
Diluted
$
0.20
$
0.19
$
0.21
Weighted-average common shares outstanding, basic
106
106
106
Weighted-average common shares outstanding, diluted
107
107
107
Expand
DNOW INC.
SUPPLEMENTAL INFORMATION (CONTINUED)
U.S. GENERALLY ACCEPTED ACCOUNTING PRINCIPLES (GAAP) TO NON-GAAP RECONCILIATIONS
In an effort to provide investors with additional information regarding our results as determined by GAAP, we disclose various non-GAAP financial measures in our quarterly earnings press releases and other public disclosures. The non-GAAP financial measures include: (i) earnings before interest, taxes, depreciation and amortization (EBITDA) excluding other costs, (ii) EBITDA excluding other costs as a percentage of revenue, (iii) net income attributable to DNOW Inc. excluding other costs, (iv) diluted earnings per share attributable to DNOW Inc. stockholders excluding other costs, and (v) free cash flow. We use these non-GAAP financial measures to evaluate and manage the Company's operations because we believe they provide useful supplemental information regarding the financial performance of our business. These non-GAAP financial measures are not intended to replace the GAAP financial measures. Free cash flow is net cash provided by (used in) operating activities adjusted for purchases of property, plant and equipment, and the remaining non-GAAP financial measures exclude the impact of certain other items. A reconciliation of each of these non-GAAP financial measures to its most comparable GAAP financial measure is included in the schedules herein. Totals in the schedules herein may not foot due to rounding.
NET INCOME ATTRIBUTABLE TO DNOW INC. TO NON-GAAP NET INCOME ATTRIBUTABLE TO DNOW INC.
(In millions)
Three Months Ended
March 31, December 31,
2025
2024
2024
GAAP net income attributable to DNOW Inc.
$
22
$
21
$
23
Other (2)
3
3
3
Other tax expense (benefit) (3)
(1
)
(1
)
−
Other, net of tax (4)*
2
2
4
Net income attributable to DNOW Inc. excluding other costs
$
24
$
23
$
27
Expand
* Totals may not foot due to rounding.
Expand
DILUTED EARNINGS PER SHARE ATTRIBUTABLE TO DNOW INC. STOCKHOLDERS TO NON-GAAP DILUTED
EARNINGS PER SHARE ATTRIBUTABLE TO DNOW INC. STOCKHOLDERS EXCLUDING OTHER COSTS
Three Months Ended
March 31, December 31,
2025
2024
2024
GAAP diluted earnings per share attributable to DNOW Inc. stockholders
$
0.20
$
0.19
$
0.21
Other, net of tax (4)
0.02
0.02
0.04
Diluted earnings per share attributable to DNOW Inc. stockholders excluding other costs
$
0.22
$
0.21
$
0.25
Expand
NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES TO FREE CASH FLOW RECONCILIATION
(UNAUDITED)
March 31, December 31, September 30, June 30, March 31,
2025
2024
2024
2024
2024
Net cash provided by (used in) operating activities
$
(16
)
$
122
$
74
$
21
$
81
Less: Purchases of property, plant and equipment
(6
)
(3
)
(2
)
(3
)
(1
)
Free cash flow
$
(22
)
$
119
$
72
$
18
$
80
Expand
(1)
Stock-based compensation excludes less than $1 million for the three months ended March 31, 2025 as such amounts were reported in Other.
(2)
For the three months ended March 31, 2025, Other primarily included approximately $2 million of transaction-related charges and $1 million of International restructuring charges, both of which were included in warehousing, selling, and administrative.
For the three months ended March 31, 2024, Other was related to transaction-related charges, including approximately $2 million in warehousing, selling and administrative, and approximately $1 million in cost of products for cost of inventory that was stepped up to fair value during purchase accounting related to an acquisition.
For the three months ended December 31, 2024, Other included transaction-related charges of approximately $2 million included in warehousing, selling and administrative, and International restructuring charges of approximately $1 million related to foreign currency translation losses included in impairment and other charges.
Transaction-related charges include transaction costs, inventory fair value step-up, retention bonus accruals and integration expenses associated with acquisitions.
(3)
For the three months ended March 31, 2025, Other tax expense (benefit) represents tax benefit of approximately $1 million related to Other. The tax effect of Other is calculated based on the nature of the item and/or the tax jurisdiction in which the item has been incurred and applying the specific tax rate or tax treatment to each item included in Other.
For the three months ended March 31, 2024, Other tax expense (benefit) represents tax benefit of approximately $1 million related to Other. The tax effect of Other is calculated based on the nature of the item and/or the tax jurisdiction in which the item has been incurred and applying the specific tax rate or tax treatment to each item included in Other.
For the three months ended December 31, 2024, Other tax expense (benefit) represents tax benefit of less than $1 million related to Other. The tax effect of Other is calculated based on the nature of the item and/or the tax jurisdiction in which the item has been incurred and applying the specific tax rate or tax treatment to each item included in Other.
(4)
Other, net of tax comprises Other and Other tax expense (benefit). See footnotes (2) and (3) for details.
Expand
Contacts
Senior Vice President and Chief Financial Officer
(281) 823-4754
Industry:
Oil/Gas
Alternative Energy
Energy
Other Energy
Utilities
DNOW Inc.
NYSE:DNOW
Release Summary
DNOW Reports First Quarter 2025 Results
Release Versions
English
Contacts
Mark Johnson
Senior Vice President and Chief Financial Officer
(281) 823-4754
More News From DNOW Inc.
Get RSS Feed
DNOW Announces Fourth Quarter and Full-Year 2024 Earnings Conference Call
DNOW Inc.
NYSE:DNOW
Release Summary
DNOW Reports First Quarter 2025 Results
Release Versions
English
Contacts
Mark Johnson
Senior Vice President and Chief Financial Officer
(281) 823-4754
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
40 minutes ago
- Yahoo
Trump Says 200% Pharma Tariffs Are Coming. Wall Street Shrugs.
When a U.S. president threatens your industry with a 200% tariff, that's not typically good news. But since Tuesday, when Donald Trump said in a cabinet meeting that imported pharmaceuticals would face a massive levy, investors have been cautiously celebrating. Despite a broad stock selloff on Friday, the NYSE Arca Pharmaceutical Index is up around 1% over the past week, compared with a basically flat performance for the S&P 500. Inside the Shadowy, Lucrative Business of 'Superfake' Luxury Handbags SpaceX to Invest $2 Billion Into Elon Musk's xAI The Best EV Deals Now Are on the Used Market That outperformance may seem puzzling, but for Wall Street, the size of the tariff matters less than the timing. The 200% figure lit up cable news chyrons, but investors focused instead on the grace period Trump floated. 'We're going to give people about a year, year and a half to come in, and after that, they're going to be tariffed,' he said. A year and a half is a long runway—and it could turn out to be even longer in practice. In a note titled 'Tariffs Schmariffs,' Jefferies analyst Akash Tewari argues that if the grace period begins some time this year and lasts for a year and a half, companies could continue importing drugs tariff-free until 2027. They could buy even more time if they stockpile during that period to cover demand at least until some time in 2028. That might give them time to build entirely new U.S. manufacturing facilities, which typically takes around four years. This doesn't mean Trump isn't getting what he wants. After all, the tariffs are meant as a threat to push companies to make more of their products in the U.S. And in this case, the threat seems to be working. Since Trump began threatening pharma with tariffs, the industry has moved on two fronts. First, companies have been stockpiling drugs at a furious pace to build a cushion. For instance, the Wall Street Journal reported last month that $36 billion worth of hormone treatments—used in popular obesity and diabetes drugs—have been shipped from Ireland this year, more than double last year's total. Second, the industry has announced major investments in U.S. manufacturing. Some of that may be political posturing, but much of it reflects a real shift. Companies increasingly see no choice but to bring production back, at least for drugs sold to American patients. Eli Lilly, for example, has announced a $27 billion plan to expand manufacturing in the U.S. Making drugs in the U.S.—and registering the intellectual property here—comes with a tax hit. That is a big reason the industry offshored production to low-tax countries like Ireland in the first place. But Trump's 'Big Beautiful Bill' offers some relief to offset the pain. The bill lets companies immediately deduct R&D expenses and equipment purchases and raises the cap on how much interest they can write off—making it a lot cheaper to build new plants at home. The upshot: with more time to prepare and a friendlier tax environment, pharma companies may barely feel the sting of tariffs. Take Merck. The company plans to produce a new version of its blockbuster drug Keytruda in the U.S. Jefferies estimates that with steps like stockpiling, gradually shifting production and trimming some costs, the hit to Merck's earnings from tariffs in 2027 and 2028 could be just 1% to 2%. That is actually better than Jefferies's earlier model for a smaller 25% tariff, which assumed fewer workarounds. The sense of a new normal settling in around Trump's second presidency might help explain why dealmaking has returned to the sector. Merck this past week announced a roughly $10 billion deal to buy Verona Pharma. That followed a series of other deal announcements, including Eli Lilly's $1.3 billion pact to acquire Verve Therapeutics. By the end of Trump's term, the U.S. pharmaceutical supply chain could look very different, with a greater share of innovative drug production happening on American soil. That would be a rare win-win—for the White House and for the industry. Write to David Wainer at Economists See Lower Recession Risk and Stronger Job Growth: WSJ Survey Can Pittsburgh's Old Steel Mills Be Turned Into an AI Hub? Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
4 No-Brainer Blue Chip Stocks to Buy With $2,000 Right Now
Blue chip companies have established sound business models that can deliver solid returns over time. These companies often operate in stable industries with steady demand for their services. They also tend to display a strong economic moat through pricing power and barriers to entry. 10 stocks we like better than Berkshire Hathaway › Investing in the stock market is one way to build enduring, long-term wealth. As an investor, you could choose to invest in high-flying growth stocks, dividend stocks that provide passive income, or more conservative investments that can preserve and grow your investments steadily over time. One strategy you can consider is investing in blue chip companies. These companies have withstood the test of time thanks to sound business models that have led to solid returns for patient investors. Blue chips typically offer reliable dividends and steady long-term growth, making them appealing to both seasoned investors and newcomers seeking to establish a solid financial foundation. Here are four blue chip stocks you can invest in today. Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B) has thrived under the leadership of its longtime CEO, Warren Buffett. Since 1965, Buffett has led the conglomerate to 20% annualized returns, or enough to turn a $100 investment into $5.5 million today. So when Buffett announced earlier this year he was stepping down at the end of 2025, it took the wind out of the sails of Berkshire Hathaway stock, which is down 12% since the announcement in early May. However, Berkshire Hathaway is a widely diversified conglomerate with holdings across numerous industries, including insurance, transportation, materials, consumer goods, and energy. Its insurance operations help generate a steady stream of cash flow, which it can invest in treasuries or equities, or use to acquire companies outright. What makes Berkshire appealing right now is its massive cash pile and positive tailwinds from higher interest rates. The Federal Reserve is cautious about cutting interest rates due to concerns about inflation stemming from higher tariffs. This has resulted in rates staying "higher for longer," and Berkshire has benefited to the tune of $2.9 billion in interest income in the first quarter. Berkshire will be under new leadership, led by CEO Greg Abel, with its investment portfolio managed by Todd Combs and Ted Weschler, the investing lieutenants tapped by Buffett and the late Charlie Munger over a decade ago. While the uncertainty around its future remains, I think it's well-capitalized and diversified enough that it's a buy at today's price. Progressive (NYSE: PGR) is the second-largest automotive insurer in the United States. What sets this blue chip company apart is its disciplined underwriting, strong brand, and direct-to-consumer model. The company relies heavily on technology and data to accurately price risk and was one of the original companies to adopt usage-based insurance, known as telematics. This approach utilizes driver data to price policies, which is one reason the company has outperformed its competitors. Progressive's track record of navigating underwriting cycles while maintaining profitability distinguishes it. Going back 23 years, the company's combined ratio has averaged 92%, which is significantly lower than the industry average of 100%. Put differently, Progressive has earned an average of $8 in underwriting profit for every $100 in premiums. As a stock, Progressive offers defensive characteristics with upside. Insurance is a stable industry that enjoys steady demand, and Progressive has demonstrated its ability to outperform its peers in underwriting profitability. The company is also well-positioned to perform if inflation and interest rates were to remain elevated. That's because it has pricing power, allowing it to adapt to rising costs, and it also earns interest on float (the cash it collects from premiums but hasn't yet paid out in claims). Its stellar long-term performance and ongoing strong underwriting make Progressive an excellent blue chip stock to consider adding to your portfolio today. Chubb (NYSE: CB) is one of the world's largest publicly traded property and casualty insurers, recognized for its underwriting discipline, global diversification, and robust balance sheet. It operates across commercial and personal lines, with a reputation for serving high-net-worth individuals and complex corporate risks. Its conservative approach to risk, coupled with a broad international footprint, has enabled it to weather economic cycles well. Chubb has been a solid dividend stock for investors, growing its payout for 32 consecutive years. With a yield of 1.4% and an average annual total return of 11.7% over the past two decades, the company offers investors a balanced combination of income and stock price appreciation. It also enjoys the benefits that Progressive does, such as pricing power and interest income, making it another solid blue chip stock to consider owning today. S&P Global (NYSE: SPGI) plays a key role in markets. The company is perhaps best known for its S&P 500 index, but it also provides credit ratings, data, and analytics. Barriers to entry make it difficult to break into the credit ratings space, and S&P Global holds a 50% share of this market. S&P Global's business model is resilient and scalable. Credit rating demand rises with bond issuance, while its index and data segments enjoy recurring fees from ETF licensing and subscriptions. The company also has low capital requirements, which enables it to enjoy high margins, recurring revenue, and a global reach. The company has raised its dividend payout for 53 years, making it an exclusive member of the Dividend Kings club. While it offers a modest dividend yield of 0.7%, when combined with its stock price appreciation, S&P Global has returned 15.3% annually over the past two decades. For investors, S&P Global offers growth and a wide moat along with steady cash flows, making it a quality blue chip stock to own today. Before you buy stock in Berkshire Hathaway, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Berkshire Hathaway wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $671,477!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,010,880!* Now, it's worth noting Stock Advisor's total average return is 1,047% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of July 7, 2025 Courtney Carlsen has positions in Berkshire Hathaway and Progressive. The Motley Fool has positions in and recommends Berkshire Hathaway, Progressive, and S&P Global. The Motley Fool has a disclosure policy. 4 No-Brainer Blue Chip Stocks to Buy With $2,000 Right Now was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Are Investors Undervaluing Cable One, Inc. (NYSE:CABO) By 29%?
Cable One's estimated fair value is US$176 based on 2 Stage Free Cash Flow to Equity Current share price of US$125 suggests Cable One is potentially 29% undervalued The US$250 analyst price target for CABO is 42% more than our estimate of fair value How far off is Cable One, Inc. (NYSE:CABO) from its intrinsic value? Using the most recent financial data, we'll take a look at whether the stock is fairly priced by projecting its future cash flows and then discounting them to today's value. This will be done using the Discounted Cash Flow (DCF) model. It may sound complicated, but actually it is quite simple! We generally believe that a company's value is the present value of all of the cash it will generate in the future. However, a DCF is just one valuation metric among many, and it is not without flaws. If you want to learn more about discounted cash flow, the rationale behind this calculation can be read in detail in the Simply Wall St analysis model. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. We're using the 2-stage growth model, which simply means we take in account two stages of company's growth. In the initial period the company may have a higher growth rate and the second stage is usually assumed to have a stable growth rate. In the first stage we need to estimate the cash flows to the business over the next ten years. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years. Generally we assume that a dollar today is more valuable than a dollar in the future, and so the sum of these future cash flows is then discounted to today's value: 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 Levered FCF ($, Millions) US$257.8m US$179.0m US$146.0m US$105.0m US$84.9m US$74.3m US$68.5m US$65.3m US$63.8m US$63.3m Growth Rate Estimate Source Analyst x6 Analyst x1 Analyst x1 Analyst x1 Est @ -19.12% Est @ -12.50% Est @ -7.87% Est @ -4.63% Est @ -2.36% Est @ -0.77% Present Value ($, Millions) Discounted @ 12% US$231 US$144 US$105 US$67.7 US$49.1 US$38.5 US$31.8 US$27.1 US$23.7 US$21.1 ("Est" = FCF growth rate estimated by Simply Wall St)Present Value of 10-year Cash Flow (PVCF) = US$739m After calculating the present value of future cash flows in the initial 10-year period, we need to calculate the Terminal Value, which accounts for all future cash flows beyond the first stage. The Gordon Growth formula is used to calculate Terminal Value at a future annual growth rate equal to the 5-year average of the 10-year government bond yield of 2.9%. We discount the terminal cash flows to today's value at a cost of equity of 12%. Terminal Value (TV)= FCF2035 × (1 + g) ÷ (r – g) = US$63m× (1 + 2.9%) ÷ (12%– 2.9%) = US$752m Present Value of Terminal Value (PVTV)= TV / (1 + r)10= US$752m÷ ( 1 + 12%)10= US$251m The total value, or equity value, is then the sum of the present value of the future cash flows, which in this case is US$990m. In the final step we divide the equity value by the number of shares outstanding. Relative to the current share price of US$125, the company appears a touch undervalued at a 29% discount to where the stock price trades currently. Valuations are imprecise instruments though, rather like a telescope - move a few degrees and end up in a different galaxy. Do keep this in mind. Now the most important inputs to a discounted cash flow are the discount rate, and of course, the actual cash flows. Part of investing is coming up with your own evaluation of a company's future performance, so try the calculation yourself and check your own assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Cable One as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 12%, which is based on a levered beta of 2.000. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business. Check out our latest analysis for Cable One Strength Debt is well covered by earnings. Weakness No major weaknesses identified for CABO. Opportunity Expected to breakeven next year. Has sufficient cash runway for more than 3 years based on current free cash flows. Good value based on P/S ratio and estimated fair value. Significant insider buying over the past 3 months. Threat Debt is not well covered by operating cash flow. Revenue is forecast to decrease over the next 2 years. Although the valuation of a company is important, it is only one of many factors that you need to assess for a company. The DCF model is not a perfect stock valuation tool. Rather it should be seen as a guide to "what assumptions need to be true for this stock to be under/overvalued?" If a company grows at a different rate, or if its cost of equity or risk free rate changes sharply, the output can look very different. Can we work out why the company is trading at a discount to intrinsic value? For Cable One, there are three additional factors you should assess: Risks: Every company has them, and we've spotted 2 warning signs for Cable One (of which 1 is concerning!) you should know about. Future Earnings: How does CABO's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart. Other High Quality Alternatives: Do you like a good all-rounder? Explore our interactive list of high quality stocks to get an idea of what else is out there you may be missing! PS. Simply Wall St updates its DCF calculation for every American stock every day, so if you want to find the intrinsic value of any other stock just search here. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
